[go: up one dir, main page]

CA2001996A1 - Methode de traitement de la cystite interstitielle - Google Patents

Methode de traitement de la cystite interstitielle

Info

Publication number
CA2001996A1
CA2001996A1 CA2001996A CA2001996A CA2001996A1 CA 2001996 A1 CA2001996 A1 CA 2001996A1 CA 2001996 A CA2001996 A CA 2001996A CA 2001996 A CA2001996 A CA 2001996A CA 2001996 A1 CA2001996 A1 CA 2001996A1
Authority
CA
Canada
Prior art keywords
interstitial cystitis
treatment
naltrexone
nalmefene
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2001996A
Other languages
English (en)
Other versions
CA2001996C (fr
Inventor
Fred P. Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Branded Pharmaceutical Products R&D Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2001996A1 publication Critical patent/CA2001996A1/fr
Application granted granted Critical
Publication of CA2001996C publication Critical patent/CA2001996C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Threshing Machine Elements (AREA)
CA002001996A 1988-11-01 1989-11-01 Methode de traitement de la cystite interstitielle Expired - Fee Related CA2001996C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US265,575 1988-11-01
US07/265,575 US4877791A (en) 1988-11-01 1988-11-01 Method of treatment for interestitial cystitis

Publications (2)

Publication Number Publication Date
CA2001996A1 true CA2001996A1 (fr) 1990-05-01
CA2001996C CA2001996C (fr) 1996-07-23

Family

ID=23011021

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002001996A Expired - Fee Related CA2001996C (fr) 1988-11-01 1989-11-01 Methode de traitement de la cystite interstitielle

Country Status (11)

Country Link
US (1) US4877791A (fr)
EP (1) EP0367533B1 (fr)
JP (1) JPH07556B2 (fr)
AT (1) ATE102830T1 (fr)
AU (1) AU623189B2 (fr)
CA (1) CA2001996C (fr)
DE (1) DE68913907T2 (fr)
DK (1) DK541189A (fr)
HK (1) HK119994A (fr)
NO (1) NO894295L (fr)
ZA (1) ZA897823B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4994466A (en) * 1990-06-14 1991-02-19 Baker Cummins Pharmaceuticals, Inc. Method of treatment for multiple sclerosis
US5057322A (en) * 1990-08-10 1991-10-15 Baker Cummins Dermatologicals, Inc. Method of treating mast cell disease
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
ES2214532T3 (es) 1995-03-03 2004-09-16 Endo Pharmaceuticals Inc. Uso de dextrorfano o dextrometorfano para el tratamiento de la incontinencia urinaria.
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
WO2000044390A1 (fr) * 1999-02-01 2000-08-03 John Lezdey Traitement de la mastocytose gastro-intestinale et de la vessie
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
WO2002081477A1 (fr) * 2001-03-30 2002-10-17 Toray Industries, Inc. Derives morphinane 7-substitues et leur utilisation medicinale
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
NZ571537A (en) * 2006-04-03 2012-06-29 Nutramax Lab Inc Stabilized pentosan polysulfate (PPS) formulations and methods of analayzing them
EP2365759B1 (fr) * 2008-12-16 2018-03-07 Hill's Pet Nutrition, Inc. Composition alimentaire contenant un anti-oxydant contribuant à inhiber les voies de libération de l'histamine chez les animaux de compagnie
WO2019227053A1 (fr) * 2018-05-25 2019-11-28 Adamis Pharmaceuticals Corporation Compositions de médicament

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU538186B2 (en) * 1980-03-07 1984-08-02 Scotia Holdings Plc Prostaglandin precursors
JPS63501717A (ja) * 1985-10-29 1988-07-14 ベーカー・カミンス・デルマトロジカルス・インコーポレーテッド 抗原誘発性アレルギ−反応を阻止するための方法および組成物
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases

Also Published As

Publication number Publication date
HK119994A (en) 1994-11-11
DK541189A (da) 1990-05-02
JPH02188525A (ja) 1990-07-24
EP0367533A3 (fr) 1991-10-02
NO894295L (no) 1990-05-02
AU623189B2 (en) 1992-05-07
CA2001996C (fr) 1996-07-23
DE68913907T2 (de) 1994-06-23
JPH07556B2 (ja) 1995-01-11
DE68913907D1 (de) 1994-04-21
ATE102830T1 (de) 1994-04-15
EP0367533B1 (fr) 1994-03-16
DK541189D0 (da) 1989-10-30
AU4385089A (en) 1990-05-10
NO894295D0 (no) 1989-10-27
EP0367533A2 (fr) 1990-05-09
ZA897823B (en) 1990-07-25
US4877791A (en) 1989-10-31

Similar Documents

Publication Publication Date Title
AU3827989A (en) Method of treatment for autoimmune diseases
AU623189B2 (en) Method of treatment for interstitial cystitis
EP0377272A3 (fr) Utilisation de nalméfène ou naltrexone pour l'obtention d'un médicament destiné au traitement de l'inflammation dans l'arthrite ou dans des maladies inflammatoires associées
EP0449247A3 (en) Pharmaceutical composition containing galanthamine for treating alcoholism
GEP20032965B (en) Pharmaceutical Compound
CA2114014A1 (fr) Systeme d'administration de medicament et methode pour traiter a l'aide de la carbamazepine les troubles psychiatriques, neurologiques et autres
GB8712073D0 (en) Medicament
GB9519661D0 (en) Fatty acid treatment
AU1189688A (en) Utilization of morphine antagonists in the preparation of drugs having an immunomodulator and antiviral effect, particularly for treating acquired immunodeficiency states
AU7807791A (en) Method of treating impotence
GR3034186T3 (en) 3,4-diarylchromans for treatment of dermatitis
AU1117092A (en) Treatment of lower urinary tract disorders
ATE78687T1 (de) Quaternaere derivate von noroxymorphon zur behandlung von uebelkeit und erbrechen.
EP0319962A3 (fr) Dérivés de la pipéridinyl méthanol pour le traitement de l'anxiété
DK0583026T3 (fr)
EP0362847A3 (fr) Emploi de l'étopéritone pour obtenir une composition pharmaceutique pour le traitement de l'impotence chez l'homme
GR3025518T3 (en) Use of the N-n-butyl derivative of desoxynojirimycin in the manufacture of a medicament inhibiting HIV-Virus
AU8166291A (en) Method of treating mast cell disease
AU2908389A (en) Device for administering medicaments by atomization in intubated or tracheotomized patients
HU906436D0 (en) Process for the production of 3-substituted 2-oxyndole-derivatives
GR3015107T3 (en) Use of zofenopril for the preparation of drugs against rheumatoid arthritis.
ZA927362B (en) Process for the production of a pharmaceutical agent for oral or topical administration in the treatment of leishmaniasis.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed